ArticleJournal of neuro-oncology2026
Fractionated stereotactic radiotherapy (fSRT) for symptomatic WHO grade 1 cavernous sinus meningiomas: long-term local control, clinical response, and toxicity outcomes.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCavernous sinus meningiomas represent a significant clinical challenge, given the high prevalence of neurological deficits and limited surgical options. Radiation therapy is often the preferred treatment. This study evaluates the effectiveness of fractionated stereotactic radiation therapy (fSRT) in achieving local control and symptomatic relief in patients with cavernous sinus meningiomas.
methodsThis is a single-institution retrospective analysis of patients with symptomatic presumed WHO grade 1 cavernous sinus meningiomas treated with fSRT (1.8-2 Gy per fraction). Clinical data were collected by chart review. Kaplan-Meier curves were generated to assess local control. Clinical responses were evaluated for symptom improvement, stability, or worsening at ≤ 36 months, 36-60 months, 60-120 months, 120-180 months, and > 180 months.
resultsThis study identified 39 patients treated with fSRT who met inclusion criteria. Median age was 60 years (range 21-79), with a median Karnofsky Performance Score (KPS) of 90. Median follow-up time was 122.2 months. Median tumor volume was 10.0 cc (range 3.6-18.3 cc). Local control rates at 1, 3, 5, and 10 years were 100%, 94.6%, 91.7%, and 88.1%, respectively. Of 39 patients, 26 (66.7%) demonstrated clinical improvement following fSRT, 9 (23.1%) remained clinically unchanged, and 4 (10.3%) experienced worsening.
conclusionOur study demonstrated fSRT achieves effective local control for cavernous sinus meningioma. Notably, 2/3 of patients achieved neurological symptom improvement after radiation. Larger, prospective studies are warranted to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.